Side-effects of checkpoint inhibitor-based combination therapy
Year: 2016
Type: article
Source: Current Opinion in Oncology
Authors: Hampig R. Kourie, Jean A. Klastersky
Institutions: Université Libre de Bruxelles, Institut Jules Bordet
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: immune checkpoint inhibitors, combination therapy, immunotherapy toxicity, nivolumab, ipilimumab, pembrolizumab, PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, vemurafenib, melanoma, non-small cell lung cancer, renal cell carcinoma, hepatotoxicity, combination targeted therapy, immune-related adverse events
Open Access status: closed
OpenAlex ID: W2343457304
